RT Journal Article
T1 Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
A1 Kahan, Zsuzsanna
A1 Gil-Gil, Miguel
A1 Ruiz-Borrego, Manuel
A1 Carrasco, Eva
A1 Ciruelos, Eva
A1 Muñoz, Montserrat
A1 Bermejo, Begoña
A1 Margeli, Mireia
A1 Anton, Antonio
A1 Casas, Maribel
A1 Csoszi, Tibor
A1 Murillo, Laura
A1 Morales, Serafin
A1 Calvo, Lourdes
A1 Lang, Istvan
A1 Alba, Emilio
A1 de-la-Haba-Rodriguez, Juan
A1 Ramos, Manuel
A1 Alvarez-Lopez, Isabel
A1 Gal-Yam, Einav
A1 Garcia-Palomo, Andres
A1 Alvarez, Elena
A1 Gonzalez-Santiago, Santiago
A1 Rodriguez, Cesar A
A1 Servitja, Sonia
A1 Corsaro, Massimo
A1 Rodrigalvarez, Graciela
A1 Zielinski, Christoph
A1 Martin, Miguel
K1 CDK4/6 inhibitor
K1 Endocrine therapy
K1 Health-related quality of life
K1 Hormone receptor–positive metastatic breast cancer
K1 Palbociclib
AB The PEARL study showed that palbociclib plus endocrine therapy (palbociclib/ET) was not superior to capecitabine in improving progression-free survival in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors, but was better tolerated. This analysis compared patient-reported outcomes. The PEARL quality of life (QoL) population comprised 537 patients, 268 randomised to palbociclib/ET (exemestane or fulvestrant) and 269 to capecitabine. Patients completed the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23 and EQ-5D-3L questionnaires. Changes from the baseline and time to deterioration (TTD) were analysed using linear mixed-effect and stratified Cox regression models, respectively. Questionnaire completion rate was high and similar between treatment arms. Significant differences were observed in the mean change in global health status (GHS)/QoL scores from the baseline to cycle 3 (2.9 for palbociclib/ET vs. -2.1 for capecitabine (95% confidence interval [CI], 1.4-8.6; P = 0.007). The median TTD in GHS/QoL was 8.3 months for palbociclib/ET versus 5.3 months for capecitabine (adjusted hazard ratio, 0.70; 95% CI, 0.55-0.89; P = 0.003). Similar improvements for palbociclib/ET were also seen for other scales as physical, role, cognitive, social functioning, fatigue, nausea/vomiting and appetite loss. No differences were observed between the treatment arms in change from the baseline in any item of the EQ-5D-L3 questionnaire as per the overall index score and visual analogue scale. Patients receiving palbociclib/ET experienced a significant delay in deterioration of GHS/QoL and several functional and symptom scales compared with capecitabine, providing additional evidence that palbociclib/ET is better tolerated. 
PB Elsevier
YR 2021
FD 2021-07-07
LK http://hdl.handle.net/10668/18401
UL http://hdl.handle.net/10668/18401
LA en
NO Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E, Muñoz M, et al. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study. Eur J Cancer. 2021 Oct;156:70-82
DS RISalud
RD Apr 7, 2025